Local injection of low‐dose ixekizumab for the treatment of palmoplantar pustular psoriasis-Reference-Cited by-同舟云学术

Local injection of low‐dose ixekizumab for the treatment of palmoplantar pustular psoriasis

Published:2022-03-29 Issue:6 Volume:61 Page:742-743
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatology

Author:

He Fang¹,Long FangYuan¹²,Yin Zhi¹,Yin ZhiQiang¹^ORCID

Affiliation:

1. Department of Dermatology First Affiliated Hospital of Nanjing Medical University Nanjing China

2. Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College Nanjing China

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.16185

Reference7 articles.

1. A brief guide to pustular psoriasis for primary care providers

2. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial

3. Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments

4. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study

5. Ixekizumab for the treatment of psoriasis: up-to-date

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local injection of micro-dose anti-interleukin-17A antibody for palmoplantar pustulosis: A real-world study;Clinical Immunology;2023-08

2. An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations;Expert Review of Clinical Immunology;2023-03-27

3. Tofacitinib combined with local low-dose ixekizumab injection benefits those with peripheral psoriatic arthritis;The Journal of Biomedical Research;2023

4. Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review;Expert Opinion on Biological Therapy;2022-08-25

5. Ixekizumab/tripterygium-glycosides;Reactions Weekly;2022-07